Residency · Residency · Medicine Pediatrics
Venous Thromboembolism: Age-Specific Risk and Management
Overview
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE) VTE is common in adults (1-2 per 1,000/year) but rare in children (~0.07-0.14 per 10,000/year) Pediatric VTE incidence is rising due to increased survival of critically ill children, central venous catheter use, and childhood obesity. Bimodal pediatric distribution: neonates and adolescents. Management principles differ substantially between children and adults.
Risk Factors
Pediatric Risk Factors
Central venous catheters: single greatest risk factor, present in >90% of neonatal and >50% of childhood VTE. Congenital heart disease and cardiac surgery; Cancer and chemotherapy (especially asparaginase); Infection/sepsis; Nephrotic syndrome (urinary loss of antithrombin); Dehydration (especially in neonates — renal vein thrombosis, cerebral venous sinus thrombosis) Immobilization, trauma, surgery; Obesity (emerging risk factor); Oral contraceptive use in adolescents; Inherited thrombophilia (lower contribution than in adults).
Adult Risk Factors
Surgery (especially orthopedic, cancer surgery), immobilization, hospitalization. Active malignancy (Trousseau syndrome); Oral contraceptives and hormone replacement therapy; Pregnancy and postpartum period; Obesity, age >60; Prior VTE (strongest predictor of recurrence); Inherited thrombophilia: Factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency, antithrombin deficiency. Acquired: antiphospholipid syndrome, myeloproliferative neoplasms.
<image>Comparison of VTE risk factors in pediatric versus adult populations showing relative contribution of central venous catheters, immobilization, thrombophilia, and hormonal factors by age group</image>
Clinical Presentation
DVT
Children: upper extremity DVT more common than lower extremity (reflects CVC-related disease); may present with limb swelling, pain, collateral vein distension, or catheter malfunction. Adults: lower extremity DVT predominates (especially left leg — May-Thurner anatomy); calf pain, swelling, warmth, Homan sign (unreliable) Neonates: renal vein thrombosis (hematuria, flank mass, thrombocytopenia), portal vein thrombosis, cerebral venous sinus thrombosis.
Pulmonary Embolism
Adults: dyspnea, pleuritic chest pain, tachycardia, hemoptysis; massive PE presents with hypotension/shock. Children: PE is likely underdiagnosed; presentation is often nonspecific (tachypnea, chest pain, hypoxia) Adolescents on OCPs with unexplained dyspnea should prompt PE consideration.
Diagnosis
Adult VTE Diagnosis
Clinical probability scores: Wells score for DVT and PE; Geneva score for PE. D-dimer: high negative predictive value in low-probability patients; age-adjusted cutoff (age x 10 for patients >50) improves specificity. Compression ultrasonography: first-line for DVT (sensitivity >95% for proximal DVT) CT pulmonary angiography (CTPA): gold standard for PE diagnosis. V/Q scan: alternative when CTPA contraindicated (contrast allergy, renal insufficiency, pregnancy consideration)
Pediatric VTE Diagnosis
Clinical probability scores are NOT validated in children. D-dimer: less useful; normal values differ by age; false positives common in neonates and infants. Ultrasound: first-line for DVT; technically challenging in small children. CTPA: used for PE but radiation exposure is a concern; balance with clinical urgency. MR venography: useful for central venous thrombosis without radiation. Echocardiography: for right heart thrombus, especially in neonates with CVC-related thrombosis.
Anticoagulation: Pediatric Versus Adult
Unfractionated Heparin (UFH)
Neonates and infants require higher weight-based doses due to lower antithrombin levels and larger volume of distribution. Pediatric loading dose: 75 U/kg bolus, then 28 U/kg/hr (infants) or 20 U/kg/hr (children >1 year) Adult: 80 U/kg bolus, then 18 U/kg/hr. Monitor with anti-Xa (preferred) or aPTT. Antithrombin supplementation may be needed in neonates who are heparin-resistant.
Low-Molecular-Weight Heparin (LMWH)
| Population | Enoxaparin Treatment Dose | Monitoring |
|---|---|---|
| Infants <2 months | 1.5 mg/kg/dose q12h | Anti-Xa levels (target 0.5-1.0 U/mL) |
| Children >2 months | 1 mg/kg/dose q12h | Anti-Xa levels (target 0.5-1.0 U/mL) |
| Adults | 1 mg/kg q12h or 1.5 mg/kg daily | Anti-Xa levels if extremes of weight/renal insufficiency |
Enoxaparin is the most studied LMWH in pediatrics. More predictable pharmacokinetics than UFH; preferred for outpatient management.
Direct Oral Anticoagulants (DOACs)
Rivaroxaban: approved for children >= 2 years for VTE treatment (based on EINSTEIN-Jr trial) Dosing is weight-based in children with special pediatric formulations. Adult: rivaroxaban 15 mg BID x 21 days then 20 mg daily; apixaban 10 mg BID x 7 days then 5 mg BID. DOACs do NOT require routine monitoring; no reliable reversal for some agents (andexanet alfa for factor Xa inhibitors) Dabigatran: approved for children >= 3 months (post-heparin treatment)
Warfarin
Previously the mainstay for long-term anticoagulation in children; now increasingly replaced by DOACs and LMWH. Challenging in children: breast milk and formula vitamin K content varies, frequent dose adjustments, dietary changes. Neonates have naturally low vitamin K-dependent factors — very sensitive to warfarin. INR target: 2.0-3.0 for most indications (same as adults) Adults: still used for mechanical heart valves, antiphospholipid syndrome, and patient/cost preference.
<image>Weight-based dosing comparison table for anticoagulants across age groups showing UFH, LMWH, rivaroxaban, and dabigatran with pediatric versus adult dosing and monitoring parameters</image>
Duration of Therapy
Pediatric Guidelines (CHEST/ASH)
CVC-related DVT: 6 weeks to 3 months (remove or replace catheter if possible); Provoked VTE (non-CVC): 3 months minimum; Unprovoked VTE: 6-12 months; Recurrent unprovoked VTE: consider extended anticoagulation; Neonatal renal vein thrombosis: 6 weeks to 3 months.
Adult Guidelines
Provoked by transient risk factor (surgery, immobilization): 3 months. Provoked by ongoing risk factor (active cancer): extended until risk resolves; LMWH or DOACs preferred for cancer-associated VTE. Unprovoked first VTE: at least 3 months, then reassess; consider extended if low bleeding risk (especially in males, elevated D-dimer after stopping, proximal DVT) Recurrent unprovoked: indefinite anticoagulation.
Thrombophilia Testing
When to Test
Not recommended routinely after provoked VTE in either children or adults; Consider in:; Unprovoked VTE in young adults or children; Family history of VTE, especially in first-degree relatives <50 years; Recurrent VTE; Unusual site thrombosis (cerebral, portal, mesenteric veins); Neonatal purpura fulminans (suspect severe protein C or S deficiency).
What to Test
Factor V Leiden mutation, prothrombin G20210A mutation. Protein C, protein S, antithrombin III activity. Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein) Homocysteine level. Timing: test BEFORE starting anticoagulation or >2 weeks after completion (warfarin lowers protein C/S; heparin lowers antithrombin; acute thrombosis affects all levels)
<image>Flowchart for thrombophilia testing decisions showing indications, timing relative to anticoagulation therapy, and interpretation of results in the context of pediatric versus adult VTE</image>
VTE Prophylaxis
Pediatric Prophylaxis
No universally accepted risk assessment model (unlike adults) Consider prophylaxis for: immobilized adolescents post-surgery, adolescents with multiple risk factors, cancer patients with CVC. LMWH at prophylactic doses: enoxaparin 0.5 mg/kg every 12 hours (children) Mechanical prophylaxis (graduated compression stockings, pneumatic compression): limited pediatric data but used empirically.
Adult Prophylaxis
Well-established guidelines (Padua score for medical, Caprini score for surgical) Pharmacologic: LMWH, UFH, or fondaparinux for hospitalized medical and surgical patients at moderate-high risk. Mechanical: sequential compression devices for low-risk or in addition to pharmacologic. Extended prophylaxis post-discharge: consider for high-risk cancer surgery (28 days) and hip/knee arthroplasty (35 days)
Special Populations
Neonatal VTE
Most common in neonatal ICU with central lines. Renal vein thrombosis: associated with dehydration, perinatal asphyxia, maternal diabetes. Cerebral venous sinus thrombosis: may present with seizures. Treatment: LMWH or UFH; warfarin extremely difficult to manage in neonates. Thrombolysis reserved for life- or organ-threatening thrombosis.
Cancer-Associated VTE
In adults, DOACs (edoxaban, rivaroxaban, apixaban) have largely replaced LMWH for non-GI cancers. GI cancers: higher GI bleeding risk with DOACs; LMWH may still be preferred. In children with cancer: LMWH remains standard; DOACs emerging but less studied in pediatric oncology.
Clinical Pearls
Upper extremity DVT in children is almost always CVC-related; in adults, consider Paget-Schroetter syndrome (effort thrombosis) or thoracic outlet syndrome. Neonatal purpura fulminans with DIC should prompt urgent testing for homozygous protein C or S deficiency — treat with protein C concentrate or FFP. DOACs have transformed pediatric VTE management but pediatric formulations (suspensions) must be used — adult tablets cannot simply be cut for smaller doses. In adolescent females on OCPs who develop VTE, discontinue hormonal contraception and offer non-estrogen alternatives (IUD, progestin-only) Post-thrombotic syndrome (chronic venous insufficiency, pain, swelling) occurs in 10-60% of children after DVT; compression stockings may reduce risk. Always consider antiphospholipid syndrome in young adults with unprovoked VTE, especially with concurrent thrombocytopenia or pregnancy complications.
References
- Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Treatment of Pediatric Venous Thromboembolism. Blood Adv. 2018;2(22):3292-3316.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.
- Albisetti M, Moeller A, Engel H, et al. Evaluation of Rivaroxaban for the Treatment of Venous Thromboembolism in Children (EINSTEIN-Jr). Blood. 2020;136(Suppl 1):34-35.
- Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr. 2017;5:68.
